| Editor's Note: The Top Line and Podnosis podcasts are taking a two-week summer break, and the Fierce Life Sciences team will resume with new episodes the week of September 4th. |
|
Digital transformation, AI, big data, and regulatory action—these four trends are shaping the healthcare industry. From new technologies to billion-dollar research funding, there are plenty of lucrative investment opportunities to be had. Learn more.
|
|
Today’s Big NewsAug 23, 2023 |
|
October 16-17 | Boston, MA
Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book your seat today and save $200!
|
|
| By Max Bayer More than six months after Johnson & Johnson merged its infectious disease and vaccine units, the healthcare giant is cutting research and development for the unit altogether, according to sources familiar with the decision. |
|
|
|
By Fraiser Kansteiner “I did not come back to FDA to spend all my time on supply chain, but that’s what’s happened,” Commissioner Robert Califf, M.D., said in response to a question about drug shortages during a recent presentation of the Alliance for a Stronger FDA. “And I feel like I know a lot about it, and I’m pretty fired up to do something about it.” |
By Andrea Park Between commercial developers like Synchron and Elon Musk’s Neuralink, and ongoing research around the globe, it may be only a matter of time before people with paralysis, ALS and other speech-limiting conditions have their communication abilities restored via “mind-reading” technology. |
By Nick Paul Taylor An “inadvertent disclosure” has given the world a look at Roche’s eagerly anticipated TIGIT data. Having kept its cards close to its chest throughout the phase 3 lung cancer study, the Swiss drugmaker published interim overall survival results Wednesday after they were mistakenly made public. |
By Fraiser Kansteiner After floating the idea earlier this month, Mallinckrodt has formally declared its intention to kick off another round of bankruptcy proceedings in the coming days. But questions remain on just how much the move will affect the company’s looming opioid payouts. |
By Angus Liu Novo Nordisk is struggling to meet strong demand for Wegovy, and the company has reportedly tapped another contract manufacturer to churn out the popular weight-loss drug. |
By Conor Hale The company is gearing up for a nationwide rollout as public hopes rise for treatments that may make some headway against the condition. |
By James Waldron The Biomedical Advanced Research and Development Authority (BARDA) has tapped Regeneron for a next-generation COVID-19 antibody therapy, promising up to $326 million in government funds in the hope of getting a candidate into the clinic this year. |
By Fraiser Kansteiner While nothing is certain yet, Apellis may be homing in on the source of a rare but serious side effect tied to its world-first geographic atrophy drug Syfovre. The safety update comes as the company links the use of its med to eight total cases of retinal vasculitis—a type of inflammation that blocks blood flow to the retina and can potentially cause blindness. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
